Side effects may include nausea and vomiting, decreased appetite and weight loss. The strong potency of<unk> , provided by its dual inhibitory mechanism, has been postulated to lead to more nausea and vomiting during the titration phase of oral<unk>  treatment. This enforces the importance of taking oral forms of these drugs with food as prescribed. However, rates of nausea and vomiting are markedly reduced with the once-daily<unk>  patch (which can be applied at any time of the day, with or without food). Patients and caregivers should be aware of warning signs of potential toxicities and know when to call their doctor. For the patch and oral formulations, skin rashes can occur at which time patients should contact their doctor immediately. For the patch, patients and caregivers should monitor for any intense itching, redness, swelling or blistering at the patch location. If this occurs, remove the patch, rinse the area and call the doctor immediately. In a large clinical trial of the<unk>  patch in 1,195 patients with Alzheimer's disease, the target dose of 9.5 mg/24-hour patch provided similar clinical effects (e.g. memory and thinking, activities of daily living, concentration) as the highest doses of<unk>  capsules, but with one-third fewer reports of nausea and vomiting. Usage of<unk>  was associated with a higher frequency of reports of death as an adverse event in the Food and Drug Administration Adverse Event Reporting System database compared to the other acetylcholinesterase inhibiting drugs donepezil and galantamine.
Rivastigmine
Perhexiline
Memantine
Bremelanotide
Bromperidol decanoate
Meptazinol
Carbidopa/levodopa
Rasagiline